Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Shares Up 1.3% - Still a Buy?

Shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) traded up 1.3% during mid-day trading on Tuesday . The stock traded as high as $7.12 and last traded at $7.09. 465,642 shares traded hands during mid-day trading, a decline of 45% from the average session volume of 846,056 shares. The stock had previously closed at $7.00.

Analyst Upgrades and Downgrades

Several research firms have commented on BAYRY. Hsbc Global Res upgraded Bayer Aktiengesellschaft to a "hold" rating in a research note on Monday, April 28th. Wall Street Zen upgraded Bayer Aktiengesellschaft from a "hold" rating to a "buy" rating in a research report on Saturday.

Bayer Aktiengesellschaft Price Performance

The stock's 50-day moving average price is $6.33 and its 200 day moving average price is $5.80. The company has a quick ratio of 0.81, a current ratio of 1.32 and a debt-to-equity ratio of 1.19. The firm has a market capitalization of $27.74 billion, a price-to-earnings ratio of -27.15 and a beta of 0.84.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported $0.65 EPS for the quarter, beating analysts' consensus estimates of $0.63 by $0.02. Bayer Aktiengesellschaft had a negative net margin of 2.02% and a positive return on equity of 16.90%. The company had revenue of $15.27 billion during the quarter, compared to the consensus estimate of $13.39 billion. Equities research analysts expect that Bayer Aktiengesellschaft will post 1.31 earnings per share for the current fiscal year.

Bayer Aktiengesellschaft Increases Dividend

The business also recently disclosed a dividend, which was paid on Monday, May 12th. Shareholders of record on Wednesday, April 30th were paid a dividend of $0.0224 per share. The ex-dividend date was Tuesday, April 29th. This represents a yield of 0.38%. This is a positive change from Bayer Aktiengesellschaft's previous dividend of $0.02. Bayer Aktiengesellschaft's payout ratio is -2.17%.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.